Home › Esophageal Squamous Cell Carcinoma › Texas › Fort Worth
Esophageal Squamous Cell Carcinoma clinical trials in Fort Worth, TX
5 studies for Esophageal Squamous Cell Carcinoma are looking for participants at sites in and around Fort Worth (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
- START Dallas Fort Worth, Fort Worth
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- START Dallas Forth Worth, Fort Worth
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
RecruitingPhase 3
- John Peter Smith Hospital, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RecruitingPhase 1
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
- START Dallas Fort Worth, LLC, Fort Worth
Esophageal Squamous Cell Carcinoma trials in other cities
- Arlington, VA14 studies
- Nashville, TN12 studies
- Houston, TX12 studies
- Los Angeles, CA11 studies
- Baldwin Park, CA8 studies
- West Valley City, UT7 studies
- San Antonio, TX7 studies
- New York City, NY7 studies
- Santa Monica, CA6 studies
- Queens, NY6 studies
- Dallas, TX5 studies
- Boston, MA5 studies
Other studies in Fort Worth
- Non-Small Cell Lung Cancer18 studies
- Ovarian Cancer17 studies
- Endometrial Cancer12 studies
- Breast Cancer12 studies
- Cancer (all types)9 studies
- Prostate Cancer9 studies
- Triple-Negative Breast Cancer7 studies
- Macular Degeneration7 studies
- Ulcerative Colitis7 studies
- Kidney Cancer (Renal Cell Carcinoma)7 studies
- Heart Failure7 studies
- Metastatic Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.